Year

2018

Status

Active

Team

Field

Target discovery

Location

Ghent (Belgium)

Fund

BGV III

Confo Therapeutics

Confo Therapeutics employs its proprietary CONFO® technology to lock inherently unstable functional conformations of GPCRs as a superior starting point for drug discovery.